Orestes Vicente Forlenza1, Aline Silva Miranda2, Izabela Guimar, Leda Leme Talib1, Breno Satler Diniz3,4, Wagner Farid Gattaz1, Antonio Lucio Teixeira2. 1. Laboratory of Neuroscience (LIM 27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil. 2. Neuroscience Branch, Interdisciplinary Laboratory of Medical Investigation, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil. 3. Department of Mental Health, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil. 4. National Institute of Science & Technology Molecular Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Abstract
BACKGROUND: There is evidence of decreased neurotrophic support in Alzheimer's disease (AD), including its prodromal stages, but it is not clear whether this abnormality represents a marker of this process. OBJECTIVE: To determine serum concentrations of a panel of neurotrophic factors (BDNF, NGF, and GDNF) in a cross-section of elderly patients with mild cognitive impairment (MCI) and AD compared to cognitively healthy controls, and to evaluate whether abnormal levels of these factors at baseline predict the transition from MCI to dementia. METHODS: A total of 134 older adults were enrolled in this study. Twenty-six patients with mild to moderate AD, 62 with MCI, and 46 cognitively healthy older adults (controls) were subjected to a clinical evaluation including several cognitive tests. Peripheral blood was drawn and serum levels of BDNF, NGF, and GDNF were measured by enzyme-linked immunosorbent assay. APOE genotyping was performed by PCR assays. RESULTS: Serum concentrations of BDNF, NGF, and GDNF were significantly reduced in cognitively impaired subjects (i.e., MCI and AD) as compared to controls, although only the former two remained statistically different after controlling for age, gender, and cognitive performance (p = 0.05 and p = 0.01, respectively). Lower BDNF and NGF levels were also observed in the sub-sample of MCI patients who progressed to dementia upon follow-up (p = 0.02 and p = 0.002, respectively). CONCLUSION: Abnormalities in neurotrophic systems are observed at early stages of AD and may represent a marker of cognitive deterioration.
BACKGROUND: There is evidence of decreased neurotrophic support in Alzheimer's disease (AD), including its prodromal stages, but it is not clear whether this abnormality represents a marker of this process. OBJECTIVE: To determine serum concentrations of a panel of neurotrophic factors (BDNF, NGF, and GDNF) in a cross-section of elderly patients with mild cognitive impairment (MCI) and AD compared to cognitively healthy controls, and to evaluate whether abnormal levels of these factors at baseline predict the transition from MCI to dementia. METHODS: A total of 134 older adults were enrolled in this study. Twenty-six patients with mild to moderate AD, 62 with MCI, and 46 cognitively healthy older adults (controls) were subjected to a clinical evaluation including several cognitive tests. Peripheral blood was drawn and serum levels of BDNF, NGF, and GDNF were measured by enzyme-linked immunosorbent assay. APOE genotyping was performed by PCR assays. RESULTS: Serum concentrations of BDNF, NGF, and GDNF were significantly reduced in cognitively impaired subjects (i.e., MCI and AD) as compared to controls, although only the former two remained statistically different after controlling for age, gender, and cognitive performance (p = 0.05 and p = 0.01, respectively). Lower BDNF and NGF levels were also observed in the sub-sample of MCI patients who progressed to dementia upon follow-up (p = 0.02 and p = 0.002, respectively). CONCLUSION:Abnormalities in neurotrophic systems are observed at early stages of AD and may represent a marker of cognitive deterioration.
Authors: Bo Yi Kim; Seon Heui Lee; Petra L Graham; Francesco Angelucci; Alejandro Lucia; Helios Pareja-Galeano; Thomas Leyhe; Yuda Turana; I Re Lee; Ji Hye Yoon; Jae Il Shin Journal: Mol Neurobiol Date: 2016-11-04 Impact factor: 5.590
Authors: Joanne S Allard; Oyonumo Ntekim; Steven P Johnson; Julius S Ngwa; Vernon Bond; Dynell Pinder; Richard F Gillum; Thomas V Fungwe; John Kwagyan; Thomas O Obisesan Journal: Exp Gerontol Date: 2016-11-15 Impact factor: 4.032
Authors: Aron S Buchman; Lei Yu; Patricia A Boyle; Julie A Schneider; Philip L De Jager; David A Bennett Journal: Neurology Date: 2016-01-27 Impact factor: 9.910